Valneva SE (VLA.VI)
- GlobeNewswire
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE
VALNEVA Declaration of shares and voting rights April 30, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: May 6, 2024 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was
- GlobeNewswire
Declaration of voting rights - Valneva SE, March 2024
VALNEVA Declaration of shares and voting rights March 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: April 4, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was
- GlobeNewswire
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). There are currently no preventive vaccines or effective treatments available against ZIKV. As such, this mosquito-borne disease remains a public health threat and is i
